ATI

ATI

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Industrials

industry

Metal Fabrication

Exchange

NYSE

County of HQ

United States

Next Earnings Date

04/30/26

Business Summary

Alto Neuroscience operates as a clinical-stage biotechnology company focused on developing targeted therapies, likely monetizing value through successful drug development, partnerships, and eventual commercialization or acquisition. Cash generation in this model typically comes from milestone payments, licensing agreements, or post-approval drug sales rather than current operating income. The moat, if it exists, lies in proprietary clinical data, differentiated neurological targeting approaches, and intellectual property protection. Until commercialization, its competitive edge depends on capital access, scientific differentiation, and the ability to convert research into defensible therapeutic assets.

VALUATION

P/E

56.8

Market Cap ($M USD)

$22,135

Forward P/E

32.1

PEG

2.2

PRICE TO SALES

5

PRICE TO BOOK

12.3

EV / EBITDA

29.3

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$2.92

Next Year EPS Growth Estimate

$5.06

Next Year Revenue Growth Estimate

8.60%

Return on Equity (ROE)

22.40%

Operating Margin

14.00%

Debt-to-Equity

1

Piotroski F-Score

7

Altman Z-Score

6

Return on Invested Capital (ROIC)

13.20%%

Current Ratio

2.7

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a pure speculative biotech with no earnings, no forward P/E, and a deeply negative EPS of -9.6, meaning valuation cannot be grounded in cash flow or profitability. The absence of Forward P/E and PEG confirms there is no near-term earnings visibility, while ROIC at -39.20% and operating margin at -41.80% show a business structurally burning capital. However, the Altman Z-Score of 11.4 combined with a very strong Current Ratio of 15.7 signals virtually no near-term bankruptcy risk despite losses — the balance sheet is heavily cushioned. At a $727M market cap and Price/Book of 4.8, the market is paying a premium to book for optionality, not fundamentals; this is a balance-sheet-safe but fundamentally unprofitable speculation, not a mispriced compounder.

AI Exposure / Tech Reliance

As a Biotechnology company within Healthcare, Alto Neuroscience operates in a sector increasingly driven by AI-enabled drug discovery, biomarker targeting, and data-driven clinical trials. The industry’s competitive edge is shifting toward precision medicine and computational biology, areas where AI integration can materially compress development timelines. While no direct AI metrics are provided, biotech as a category is structurally leveraged to modern data science advancements.

The Bull Case

A value-oriented biotech investor could argue the balance sheet strength is the core attraction: an Altman Z-Score of 11.4 and a Current Ratio of 15.7 indicate exceptional liquidity and minimal insolvency risk. Despite deeply negative ROIC (-39.20%) and operating margin (-41.80%), the company is early-stage, and biotechnology economics often justify front-loaded losses. The $727M market cap paired with institutional ownership at $34.88 suggests serious capital has validated the pipeline’s potential. For investors seeking asymmetric upside, the absence of debt stress and the modest 0.2 yield imply capital is being preserved for growth rather than servicing liabilities.

The Bear Case

The red flags are severe and impossible to ignore: EPS of -9.6, expected EPS next year of -2.19, and Sales Growth Next Year listed at -$2.28 suggest continued losses with no clear inflection point. A Piotroski F-Score of 2 signals extremely weak fundamental quality, typically associated with deteriorating financial health. There is no Forward P/E, no PEG, no Return on Equity, and no Debt/Equity disclosed — investors are flying blind on capital structure efficiency. Paying 4.8x book for a company generating -39.20% ROIC and -41.80% operating margins is paying for hope, not performance.

Market Sentiment & Smart Money

Short Interest %

3.20%

Analyst Consensus

1.18

Average Analyst Price Target

$161.40

Institutional Ownership %

87.60%

1-Year Beta

1.6

Insider Buying % (6 Mo)

1.00%%

Distance to 52-Week High

96.50%%

Distance to 52-Week Low

369.00%%